Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 juin 2023 06h00 HE | Source: Enterome

Enterome's new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma

EO2463 uniquely targets four distinct B cell markers to maximize tumor killing and prevent immune escape, generating fast, strong and durable CD8+ T cell activation against malignant B cells ...
31 mai 2023 06h00 HE | Source: Enterome

Enterome announces sustained positive clinical outcomes with EO2401, its lead OncoMimics™ immunotherapy, in combination therapy in Glioblastoma at ASCO

Updated clinical data highlight promising efficacy and sustained CD8+ T cell expansion Early data from final cohort could provide validation of the EO2401 + nivolumab + bevacizumab combination...
09 mai 2023 06h00 HE | Source: Enterome

Enterome forms Scientific Advisory Board and Medical Advisory Group as it advances its OncoMimics™ immunotherapy pipeline for solid and liquid tumors

SAB and MAG comprise global key opinion leaders in translational tumor immunology and immunotherapy Paris, France – May 9, 2023 Enterome, a clinical-stage company developing first-in-class...
10 mars 2023 07h00 HE | Source: Enterome

Enterome's Management to Attend Upcoming Meetings

Paris, France – March 10, 2023 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, today...